SCHEMBL6648802

SCHEMBL6648802

CCOC(=O)c1cnc(SC)nc1N1CCC(C)CC1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.79
KMT2A Q03164 2/20 0.79
FOS P01100 1/20 0.49
JUN P05412 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
ALDH1A1 P00352 5/20 0.49
TDP1 Q9NUW8 2/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.47
SYK P43405 2/20 0.47
MAPT P10636 5/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 2/20 0.46
DYRK1A Q13627 1/20 0.46
ALOX15 P16050 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378685 0.87 MEN1 (0.72) MEN1KMT2AFOSJUNNFKB1
SCHEMBL6649288 0.86 KMT2A (0.57) MEN1KMT2AFOSJUNNFKB1
SCHEMBL22601477 0.85 MEN1 (0.80) MEN1KMT2AFOSJUNNFKB1
SCHEMBL6644808 0.83 KMT2A (0.53) MEN1KMT2AGAAMAPTKDM4E
SCHEMBL22440417 0.82 MEN1 (0.76) MEN1KMT2AFOSJUNNFKB1
SCHEMBL6644586 0.81 MEN1 (0.52) MEN1KMT2AFOSJUNNFKB1
SCHEMBL9492489 0.79 MEN1 (0.70) MEN1KMT2AFOSJUNNFKB1
SCHEMBL27087966 0.77 MEN1 (0.58) MEN1KMT2AFOSJUNNFKB1
SCHEMBL29867479 0.77 MEN1 (0.58) MEN1KMT2AFOSJUNNFKB1
SCHEMBL12929406 0.77 ALDH1A1 (0.64) MEN1KMT2AALDH1A1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR MEN1 3820/4885KMT2A 916/4885FOS 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.